Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been largely disappointing, and any potential success has been limited by the lack of validated predictive biomarkers for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology Jg. 12; H. 5; S. 571 - 597
Hauptverfasser:	Simpson, Aaron, Petnga, Wilfride, Macaulay, Valentine M., Weyer-Czernilofsky, Ulrike, Bogenrieder, Thomas
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.10.2017 Springer Nature B.V
Schlagworte:	Antineoplastic Agents - pharmacology Biomedicine Cancer Drug Resistance, Neoplasm - physiology Humans Insulin Insulin-like growth factors Ligands Medicine Medicine & Public Health Metabolism Neoplasms - drug therapy Oncology Receptor, IGF Type 1 - antagonists & inhibitors Review Review Article Targeted cancer therapy Treatment resistance
ISSN:	1776-2596, 1776-260X, 1776-260X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!